Three cancer drugs at very different stages. Afatinib is an approved lung-cancer drug with strong proof it slows growth and modestly extends life, though it often causes diarrhea and rash. Daraxonrasib is a newer drug showing early promise against several tumor types. SD-36 remains experimental, tested only in cells and mice. (Full Review)

Protocol

Afatinib

40 mg once daily

Oral, empty stomach (no food 3h before, 1h after); continued until progression or unacceptable toxicity

Daraxonrasib

300 mg once daily

Oral, once daily; investigational phase 3 dose, available only in trials

Pre-treatment testing

Driver-mutation genotyping

Decisive step: EGFR mutation type for afatinib, RAS variant for daraxonrasib, before starting

Time to effect

Afatinib tumor response

4–8 weeks

Responses in sensitive EGFR-mutant lung cancer often seen on first imaging

Daraxonrasib response

First cycles

Responses in trials emerge over the first treatment cycles

SD-36

No human timeframe

Never tested in humans; no human timeframe exists

Benefits

High: Afatinib delays cancer progression in EGFR-mutant non-small cell lung cancer; afatinib modestly extends overall survival

Medium: Daraxonrasib shrinks tumors in previously treated RAS-mutant pancreatic cancer; broad activity across RAS-mutant tumor types

Low: Afatinib activity in head and neck and other ErbB-driven cancers

Speculative: SD-36 tumor regression in STAT3-dependent cancers; immune-modulating anticancer effects

Contraindications

No relevant tumor driver (no EGFR mutation for afatinib; no RAS mutation for daraxonrasib)

Known interstitial lung disease (afatinib)

Severe uncontrolled diarrhea

Pregnancy or breastfeeding

Severe hepatic impairment (Child-Pugh Class C, afatinib)

Poor performance status (ECOG 3–4)

Key Interactions

P-glycoprotein inhibitors (ritonavir, ketoconazole, verapamil, cyclosporine)

P-glycoprotein inducers (rifampicin, carbamazepine, St. John's wort)

Daraxonrasib transporter/enzyme inhibitors or inducers

St. John's wort

Diarrhea-inducing supplements (high-dose magnesium, magnesium citrate, high-dose vitamin C, herbal laxatives)

NSAIDs and other kidney- or gut-stressing agents

Chemotherapy, immunotherapy, or other targeted drugs

Risk & Side Effects

High: Afatinib diarrhea; afatinib skin rash and acneiform eruption; daraxonrasib rash, mucositis, and gastrointestinal effects

Medium: Afatinib paronychia; afatinib stomatitis and mucositis

Low: Afatinib hepatotoxicity; afatinib interstitial lung disease

Speculative: Daraxonrasib long-term and wild-type RAS-related toxicities; SD-36 unknown human safety profile

Monitoring

Marker	Target	Why
Driver mutation status (EGFR, RAS, phospho-STAT3)	Activating driver present	Confirms the tumor is likely to respond
ALT / AST (liver enzymes)	Ideally <30 U/L	Detects afatinib/daraxonrasib liver stress early
Serum creatinine / eGFR	eGFR >90 mL/min/1.73m²	Flags dehydration-related kidney strain from diarrhea
Serum electrolytes (potassium, magnesium, sodium)	Mid-normal range	Detects losses from diarrhea and vomiting
Complete blood count	Normal ranges	Screens for marrow or infection effects, especially in combinations
Circulating tumor DNA (ctDNA) driver level	Declining / cleared on treatment	Early signal of response or resistance

Cadence: Baseline before starting, then roughly 1–2 weeks, every 3–4 weeks early in treatment, imaging every 6–8 weeks, extending to every 3 months once stable

Qualitative Assessment

Reduction in cancer-related symptoms (pain, breathlessness, appetite)
Energy and fatigue levels day to day
Severity and control of diarrhea, rash, and mouth soreness
Overall functional status and ability to carry out normal activities

Daraxonrasib, Afatinib & SD-36 to Treat Cancer

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment